Molecular epidemiology and carcinogenesis: endogenous and exogenous carcinogens.

[1]  T. Billiar,et al.  Nitric Oxide Suppresses Apoptosis via Interrupting Caspase Activation and Mitochondrial Dysfunction in Cultured Hepatocytes* , 1999, The Journal of Biological Chemistry.

[2]  G. Pfeifer,et al.  Quantitation and mapping of aflatoxin B1-induced DNA damage in genomic DNA using aflatoxin B1-8,9-epoxide and microsomal activation systems. , 1999, Mutation research.

[3]  C. Harris,et al.  Hepatitis B virus X protein inhibits nucleotide excision repair , 1999, International journal of cancer.

[4]  J. Pfeilschifter,et al.  Differential regulation of vascular endothelial growth factor and its receptor fms-like-tyrosine kinase is mediated by nitric oxide in rat renal mesangial cells. , 1999, The Biochemical journal.

[5]  J. Ford,et al.  Hepatitis B x Protein Inhibits p53-dependent DNA Repair in Primary Mouse Hepatocytes* , 1998, The Journal of Biological Chemistry.

[6]  A. Riggs,et al.  The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B1 adducts , 1998, Oncogene.

[7]  C. Harris,et al.  p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells , 1998, Nature Medicine.

[8]  M. Buendia,et al.  p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro , 1998, Oncogene.

[9]  Harris Cc,et al.  Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. , 1998 .

[10]  D. V. van Thiel,et al.  Pathogenesis of hepatitis B and C‐induced hepatocellular carcinoma , 1998, Journal of viral hepatitis.

[11]  E. Masini,et al.  Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. , 1998, Journal of the National Cancer Institute.

[12]  C. Harris,et al.  Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. , 1998, Cancer research.

[13]  Y. Yun,et al.  X-gene Product of Hepatitis B Virus Induces Apoptosis in Liver Cells* , 1998, The Journal of Biological Chemistry.

[14]  C. Harris,et al.  Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[15]  P. Hainaut,et al.  Hepatocellular carcinoma: from gene to public health. , 1997, Journal of the National Cancer Institute.

[16]  G. Garcı́a-Cardeña,et al.  Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. , 1997, The Journal of clinical investigation.

[17]  K. Koike,et al.  Cytoplasmic retention of the p53 tumor suppressor gene product is observed in the hepatitis B virus X gene-transfected cells , 1997, Oncogene.

[18]  Chien-Jen Chen,et al.  Epidemiological characteristics and risk factors of hepatocellular carcinoma , 1997, Journal of gastroenterology and hepatology.

[19]  Richard Graham Knowles,et al.  Selective inhibition of inducible nitric oxide synthase inhibits tumor growth in vivo: studies with 1400W, a novel inhibitor. , 1997, Cancer research.

[20]  H. Tajiri,et al.  Induction of vascular endothelial growth factor by nitric oxide in human glioblastoma and hepatocellular carcinoma cells , 1997, Oncogene.

[21]  C. Harris,et al.  Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines. , 1997, Carcinogenesis.

[22]  Jen-kun Lin,et al.  Suppression of nitric oxide–induced apoptosis by N‐acetyl‐l‐cysteine through modulation of glutathione, bcl‐2, and bax protein levels , 1997, Molecular carcinogenesis.

[23]  S. Ambs,et al.  Chronic hepatitis C virus infection in humans: induction of hepatic nitric oxide synthase and proposed mechanisms for carcinogenesis. , 1997, The Journal of surgical research.

[24]  C. Harris,et al.  Interactive effects of nitric oxide and the p 53 tumor suppressor gene in carcinogenesis and tumor progression , 2004 .

[25]  G. Wogan,et al.  UV-induced mutagenesis of human p53 in a vector replicated in Saccharomyces cerevisiae. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[26]  G. Tozer,et al.  Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. , 1997, Cancer research.

[27]  M. Nehls,et al.  Suppression of Apoptosis by Nitric Oxide via Inhibition of Interleukin-1β–converting Enzyme (ICE)-like and Cysteine Protease Protein (CPP)-32–like Proteases , 1997, The Journal of experimental medicine.

[28]  Simon C Watkins,et al.  Constitutive expression of inducible nitric oxide synthase in the mouse ileal mucosa. , 1997, The American journal of physiology.

[29]  S. Tannenbaum,et al.  The role of nitric oxide (NO.) in the carcinogenic process. , 1996, Biochimica et biophysica acta.

[30]  B. Brüne,et al.  Nitric oxide-induced apoptosis: p53-dependent and p53-independent signalling pathways. , 1996, The Biochemical journal.

[31]  J. Jiricny,et al.  Base analog and neighboring base effects on substrate specificity of recombinant human G:T mismatch-specific thymine DNA-glycosylase. , 1996, Biochemistry.

[32]  J. Weidner,et al.  Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. , 1996, Gastroenterology.

[33]  M. Hentze,et al.  Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  E. Fontham,et al.  Inducible nitric oxide synthase, nitrotyrosine, and apoptosis in Helicobacter pylori gastritis: effect of antibiotics and antioxidants. , 1996, Cancer research.

[35]  M. Oren,et al.  p53 in growth control and neoplasia. , 1996, Biochimica et biophysica acta.

[36]  C. Harris,et al.  The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. , 1996, Genes & development.

[37]  C. Harris,et al.  An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. , 1996, Carcinogenesis.

[38]  C. Harris,et al.  Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[39]  H. Whittle,et al.  Aflatoxin exposure and cytogenetic alterations in individuals from the Gambia, West Africa. , 1996, Mutation research.

[40]  Harris Cc,et al.  The 1995 Walter Hubert Lecture--molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene. , 1996, British Journal of Cancer.

[41]  C. Harris,et al.  Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. , 1995, Cancer research.

[42]  H. Loiseau,et al.  Differential expression of inducible nitric oxide synthase mRNA in human brain tumours , 1995, Neuroreport.

[43]  A. Sica,et al.  A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter , 1995, The Journal of experimental medicine.

[44]  V. Wahn,et al.  Nitric oxide induces apoptosis in mouse thymocytes. , 1995, Journal of immunology.

[45]  S. Erzurum,et al.  Continuous nitric oxide synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Richard Graham Knowles,et al.  Nitric oxide synthase activity in human breast cancer. , 1995, British Journal of Cancer.

[47]  C. Prives,et al.  Activation of p53 sequence-specific DNA bindingby short single strands of DNA requires the p53 C-terminus , 1995, Cell.

[48]  C. Harris,et al.  Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. , 1995, Oncogene.

[49]  A. Levine,et al.  Human TAFII31 protein is a transcriptional coactivator of the p53 protein. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[50]  P Rhodes,et al.  Roles of nitric oxide in tumor growth. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[51]  S. Friend,et al.  Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo. , 1995, Oncogene.

[52]  N. Pavletich,et al.  Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms , 1995, Science.

[53]  K. Isselbacher,et al.  p53-mediated cellular response to DNA damage in cells with replicative hepatitis B virus. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[54]  K. Aldape,et al.  Expression of nitric oxide synthase in human central nervous system tumors. , 1995, Cancer research.

[55]  C. Arrowsmith,et al.  Solution structure of the tetrameric minimum transforming domain of p53 , 1995, Nature Structural Biology.

[56]  C. Bréchot,et al.  Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma , 1995, Hepatology.

[57]  A. Gronenborn,et al.  HIGH-RESOLUTION SOLUTION STRUCTURE OF THE OLIGOMERIZATION DOMAIN OF P53 BY MULTI-DIMENSIONAL NMR , 1995 .

[58]  R. Tjian,et al.  p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. , 1995, Science.

[59]  A. Levine,et al.  Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression , 1995, Molecular and cellular biology.

[60]  B. Brüne,et al.  p53 expression in nitric oxide‐induced apoptosis , 1994, FEBS letters.

[61]  R. Schneider,et al.  Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[62]  D. Lane,et al.  Allosteric activation of latent p53 tetramers , 1994, Current Biology.

[63]  Carl Nathan,et al.  Nitric oxide synthases: Roles, tolls, and controls , 1994, Cell.

[64]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[65]  P. Cerutti,et al.  Oxy-radical induced mutagenesis of hotspot codons 248 and 249 of the human p53 gene. , 1994, Oncogene.

[66]  T. Kunkel,et al.  Error-prone replication of repeated DNA sequences by T7 DNA polymerase in the absence of its processivity subunit. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[67]  A. Gronenborn,et al.  High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. , 1994, Science.

[68]  John Calvin Reed,et al.  Identification of a p53-dependent negative response element in the bcl-2 gene. , 1994, Cancer research.

[69]  C. Harris,et al.  Geographic variation of p53 mutational profile in nonmalignant human liver. , 1994, Science.

[70]  A. Levine,et al.  Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. , 1994, Genes & development.

[71]  F. Ponchel,et al.  Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis. , 1994, Cancer research.

[72]  T. Soussi,et al.  Multifactorial analysis of p53 alteration in human cancer: A review , 1994, International journal of cancer.

[73]  H. Maeda,et al.  Enhanced Vascular Permeability in Solid Tumor Is Mediated by Nitric Oxide and Inhibited by Both New Nitric Oxide Scavenger and Nitric Oxide Synthase Inhibitor , 1994, Japanese journal of cancer research : Gann.

[74]  C. Harris,et al.  Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[75]  H. Bartsch,et al.  Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. , 1994, Mutation research.

[76]  Richard Graham Knowles,et al.  Nitric oxide synthase activity in human gynecological cancer. , 1994, Cancer research.

[77]  K. Isselbacher,et al.  Genetic heterogeneity of hepatocellular carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[78]  L. Szekely,et al.  p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[79]  C. Harris,et al.  p53: at the crossroads of molecular carcinogenesis and risk assessment. , 1993, Science.

[80]  P. Cerutti,et al.  Aflatoxin B1 induces the transversion of G-->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[81]  P Tomboulian,et al.  Diffusion of nitric oxide in the aorta wall monitored in situ by porphyrinic microsensors. , 1993, Biochemical and biophysical research communications.

[82]  M. Subler,et al.  p53 binds to the TATA-binding protein-TATA complex. , 1993, The Journal of biological chemistry.

[83]  M. Marletta,et al.  Nitric oxide synthase structure and mechanism. , 1993, The Journal of biological chemistry.

[84]  C. Miller,et al.  The p53 activation domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neighboring p53 domain inhibits transcription , 1993, Molecular and cellular biology.

[85]  J. Pipas,et al.  Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53 , 1993, Nature.

[86]  M. Zhu,et al.  Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. , 1993, Oncogene.

[87]  C. Ingles,et al.  Direct interaction between the transcriptional activation domain of human p53 and the TATA box-binding protein. , 1993, The Journal of biological chemistry.

[88]  Y. Cao,et al.  Aberrations of p53 gene in human hepatocellular carcinoma from China. , 1993, Carcinogenesis.

[89]  G. Zambetti,et al.  Wild-type p53 binds to the TATA-binding protein and represses transcription. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[90]  Bert Vogelstein,et al.  p53 function and dysfunction , 1992, Cell.

[91]  B. Henderson,et al.  Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma , 1992, The Lancet.

[92]  R. Iggo,et al.  Mammalian p53 can function as a transcription factor in yeast. , 1992, Nucleic acids research.

[93]  B. Slagle,et al.  p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China. , 1992, Cancer research.

[94]  A. Puisieux,et al.  Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. , 1991, Cancer research.

[95]  S. Tabata,et al.  Evidence for increased in vitro recombination with insertion of human hepatitis B virus DNA. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[96]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[97]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[98]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.

[99]  A. Siddiqui,et al.  HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions , 1991, Science.

[100]  R. A. Metcalf,et al.  Mutational hot spot in the p53 gene in human hepatocellular carcinomas , 1991, Nature.

[101]  J. Wands,et al.  Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa , 1991, Nature.

[102]  Yumay Chen,et al.  Genetic mechanisms of tumor suppression by the human p53 gene , 1990, Science.

[103]  B. Vogelstein,et al.  p53 functions as a cell cycle control protein in osteosarcomas , 1990, Molecular and cellular biology.

[104]  G. Lozano,et al.  Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. , 1990, Science.

[105]  S. Fields,et al.  Presence of a potent transcription activating sequence in the p53 protein. , 1990, Science.

[106]  B. Vogelstein,et al.  Suppression of human colorectal carcinoma cell growth by wild-type p53. , 1990, Science.

[107]  E. Appella,et al.  Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[108]  T. Soussi,et al.  Structural aspects of the p53 protein in relation to gene evolution. , 1990, Oncogene.

[109]  P. Hofschneider,et al.  A trans-activator function is generated by integration of hepatitis B virus preS/S sequences in human hepatocellular carcinoma DNA. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[110]  P. Hofschneider,et al.  The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator , 1990, Nature.

[111]  B. Freeman,et al.  Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[112]  M. Oren,et al.  Wild-type p53 can inhibit oncogene-mediated focus formation. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[113]  K. Koike,et al.  The × Gene of Hepatitis B Virus Induced Growth Stimulation and Tumorigenic Transformation of Mouse NIH3T3 Cells , 1989, Japanese journal of cancer research : Gann.

[114]  A. Levine,et al.  The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.

[115]  B. Henderson,et al.  Hepatitis B virus, aflatoxins, and hepatocellular carcinoma in southern Guangxi, China. , 1989, Cancer research.

[116]  B. Ames,et al.  Detection of DNA adducts by high-performance liquid chromatography with electrochemical detection. , 1989, Carcinogenesis.

[117]  A. Levine,et al.  Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation , 1989, Journal of virology.

[118]  O. Hino,et al.  Instability of integrated hepatitis B virus DNA with inverted repeat structure in a transgenic mouse. , 1989, Cancer genetics and cytogenetics.

[119]  Rotter,et al.  Meth A fibrosarcoma cells express two transforming mutant p53 species. , 1988, Oncogene.

[120]  A. Levine,et al.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life , 1988, Molecular and cellular biology.

[121]  D. Spandau,et al.  trans-activation of viral enhancers by the hepatitis B virus X protein , 1988, Journal of virology.

[122]  J. Twu,et al.  Transcriptional trans-activating function of hepatitis B virus , 1987, Journal of virology.

[123]  J. Kaldor,et al.  Aflatoxin exposure, hepatitis b virus infection and liver cancer in swaziland , 1987, International journal of cancer.

[124]  I. Purchase,et al.  Hepatocellular carcinoma and dietary aflatoxin in Mozambique and Transkei. , 1985, British Journal of Cancer.

[125]  V. Rotter,et al.  Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation , 1984, Nature.

[126]  P. Gruss,et al.  Participation of p53 cellular tumour antigen in transformation of normal embryonic cells , 1984, Nature.

[127]  J. Jenkins,et al.  Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53 , 1984, Nature.

[128]  V. Rotter,et al.  Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene , 1984, Cell.

[129]  C. Harris,et al.  Activation of chemical carcinogens by cultured human fetal liver, esophagus and stomach. , 1984, Chemico-biological interactions.

[130]  L. Salamat,et al.  A case-control dietary study of primary liver cancer risk from aflatoxin exposure. , 1982, International journal of epidemiology.

[131]  Lu-Yu Hwang,et al.  HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS A Prospective Study of 22 707 Men in Taiwan , 1981, The Lancet.

[132]  Patricia Rodriguez-Tomé,et al.  IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools , 1998, Nucleic Acids Res..

[133]  C. Harris,et al.  Radon and lung carcinogenesis: mutability of p53 codons 249 and 250 to 238Pu alpha-particles in human bronchial epithelial cells. , 1997, Carcinogenesis.

[134]  James B. Mitchell,et al.  Chemical biology of nitric oxide: regulation and protective and toxic mechanisms. , 1996, Current topics in cellular regulation.

[135]  Thierry Soussi,et al.  Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation , 1996, Nucleic Acids Res..

[136]  M. Evans,et al.  p53 modulation of TFIIH–associated nucleotide excision repair activity , 1995, Nature Genetics.

[137]  S. Ullrich,et al.  Functional inactivation but not structural mutation of p53 causes liver cancer , 1995, Nature Genetics.

[138]  B. Brüne,et al.  Mechanisms for nitric oxide-induced cell death: involvement of apoptosis. , 1995, Advances in neuroimmunology.

[139]  W. Robinson,et al.  Molecular events in the pathogenesis of hepadnavirus-associated hepatocellular carcinoma. , 1994, Annual review of medicine.

[140]  C. Harris.  Solving the viral-chemical puzzle of human liver carcinogenesis. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[141]  S. Snyder,et al.  Nitric oxide: a physiologic messenger molecule. , 1994, Annual review of biochemistry.

[142]  P. Cerutti,et al.  Mutagenesis of codon 248 of the human p53 tumor suppressor gene by N-ethyl-N-nitrosourea. , 1994, Oncogene.

[143]  B. Henderson,et al.  A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[144]  S. N. Agoff,et al.  Regulation of the human hsp70 promoter by p53. , 1993, Science.